447 related articles for article (PubMed ID: 29802158)
21. CHK1 protects oncogenic KRAS-expressing cells from DNA damage and is a target for pancreatic cancer treatment.
Klomp JE; Lee YS; Goodwin CM; Papke B; Klomp JA; Waters AM; Stalnecker CA; DeLiberty JM; Drizyte-Miller K; Yang R; Diehl JN; Yin HH; Pierobon M; Baldelli E; Ryan MB; Li S; Peterson J; Smith AR; Neal JT; McCormick AK; Kuo CJ; Counter CM; Petricoin EF; Cox AD; Bryant KL; Der CJ
Cell Rep; 2021 Nov; 37(9):110060. PubMed ID: 34852220
[TBL] [Abstract][Full Text] [Related]
22. Real-time Genomic Characterization of Advanced Pancreatic Cancer to Enable Precision Medicine.
Aguirre AJ; Nowak JA; Camarda ND; Moffitt RA; Ghazani AA; Hazar-Rethinam M; Raghavan S; Kim J; Brais LK; Ragon D; Welch MW; Reilly E; McCabe D; Marini L; Anderka K; Helvie K; Oliver N; Babic A; Da Silva A; Nadres B; Van Seventer EE; Shahzade HA; St Pierre JP; Burke KP; Clancy T; Cleary JM; Doyle LA; Jajoo K; McCleary NJ; Meyerhardt JA; Murphy JE; Ng K; Patel AK; Perez K; Rosenthal MH; Rubinson DA; Ryou M; Shapiro GI; Sicinska E; Silverman SG; Nagy RJ; Lanman RB; Knoerzer D; Welsch DJ; Yurgelun MB; Fuchs CS; Garraway LA; Getz G; Hornick JL; Johnson BE; Kulke MH; Mayer RJ; Miller JW; Shyn PB; Tuveson DA; Wagle N; Yeh JJ; Hahn WC; Corcoran RB; Carter SL; Wolpin BM
Cancer Discov; 2018 Sep; 8(9):1096-1111. PubMed ID: 29903880
[TBL] [Abstract][Full Text] [Related]
23. Oncogenic KRAS supports pancreatic cancer through regulation of nucleotide synthesis.
Santana-Codina N; Roeth AA; Zhang Y; Yang A; Mashadova O; Asara JM; Wang X; Bronson RT; Lyssiotis CA; Ying H; Kimmelman AC
Nat Commun; 2018 Nov; 9(1):4945. PubMed ID: 30470748
[TBL] [Abstract][Full Text] [Related]
24. Paraoxonase 2 Facilitates Pancreatic Cancer Growth and Metastasis by Stimulating GLUT1-Mediated Glucose Transport.
Nagarajan A; Dogra SK; Sun L; Gandotra N; Ho T; Cai G; Cline G; Kumar P; Cowles RA; Wajapeyee N
Mol Cell; 2017 Aug; 67(4):685-701.e6. PubMed ID: 28803777
[TBL] [Abstract][Full Text] [Related]
25. Nicotine promotes initiation and progression of KRAS-induced pancreatic cancer via Gata6-dependent dedifferentiation of acinar cells in mice.
Hermann PC; Sancho P; Cañamero M; Martinelli P; Madriles F; Michl P; Gress T; de Pascual R; Gandia L; Guerra C; Barbacid M; Wagner M; Vieira CR; Aicher A; Real FX; Sainz B; Heeschen C
Gastroenterology; 2014 Nov; 147(5):1119-33.e4. PubMed ID: 25127677
[TBL] [Abstract][Full Text] [Related]
26. Identification of tumors with NRG1 rearrangement, including a novel putative pathogenic UNC5D-NRG1 gene fusion in prostate cancer by data-drilling a de-identified tumor database.
Ptáková N; Martínek P; Holubec L; Janovský V; Vančurová J; Grossmann P; Navarro PA; Rodriguez Moreno JF; Alaghehbandan R; Hes O; Májek O; Pešek M; Michal M; Ondič O
Genes Chromosomes Cancer; 2021 Jul; 60(7):474-481. PubMed ID: 33583086
[TBL] [Abstract][Full Text] [Related]
27. Molecular Characterization of KRAS Wild-type Tumors in Patients with Pancreatic Adenocarcinoma.
Philip PA; Azar I; Xiu J; Hall MJ; Hendifar AE; Lou E; Hwang JJ; Gong J; Feldman R; Ellis M; Stafford P; Spetzler D; Khushman MM; Sohal D; Lockhart AC; Weinberg BA; El-Deiry WS; Marshall J; Shields AF; Korn WM
Clin Cancer Res; 2022 Jun; 28(12):2704-2714. PubMed ID: 35302596
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of Aurora Kinase A Induces Necroptosis in Pancreatic Carcinoma.
Xie Y; Zhu S; Zhong M; Yang M; Sun X; Liu J; Kroemer G; Lotze M; Zeh HJ; Kang R; Tang D
Gastroenterology; 2017 Nov; 153(5):1429-1443.e5. PubMed ID: 28764929
[TBL] [Abstract][Full Text] [Related]
29. A special subtype: Revealing the potential intervention and great value of KRAS wildtype pancreatic cancer.
Xu ZH; Wang WQ; Liu L; Lou WH
Biochim Biophys Acta Rev Cancer; 2022 Jul; 1877(4):188751. PubMed ID: 35732240
[TBL] [Abstract][Full Text] [Related]
30. PIN1 Maintains Redox Balance via the c-Myc/NRF2 Axis to Counteract Kras-Induced Mitochondrial Respiratory Injury in Pancreatic Cancer Cells.
Liang C; Shi S; Liu M; Qin Y; Meng Q; Hua J; Ji S; Zhang Y; Yang J; Xu J; Ni Q; Li M; Yu X
Cancer Res; 2019 Jan; 79(1):133-145. PubMed ID: 30355620
[TBL] [Abstract][Full Text] [Related]
31. Exceptional response to Erlotinib monotherapy in EGFR Exon 19-deleted, KRAS wild-type, Chemo-refractory advanced pancreatic adenocarcinoma.
Park R; Al-Jumayli M; Miller K; Saeed A; Saeed A
Cancer Treat Res Commun; 2021; 27():100342. PubMed ID: 33611092
[TBL] [Abstract][Full Text] [Related]
32. Adaptive and Reversible Resistance to Kras Inhibition in Pancreatic Cancer Cells.
Chen PY; Muzumdar MD; Dorans KJ; Robbins R; Bhutkar A; Del Rosario A; Mertins P; Qiao J; Schafer AC; Gertler F; Carr S; Jacks T
Cancer Res; 2018 Feb; 78(4):985-1002. PubMed ID: 29279356
[TBL] [Abstract][Full Text] [Related]
33. NRG1 fusions in breast cancer.
Howarth KD; Mirza T; Cooke SL; Chin SF; Pole JC; Turro E; Eldridge MD; Garcia RM; Rueda OM; Boursnell C; Abraham JE; Caldas C; Edwards PAW
Breast Cancer Res; 2021 Jan; 23(1):3. PubMed ID: 33413557
[TBL] [Abstract][Full Text] [Related]
34. Oncogenic
Kim MP; Li X; Deng J; Zhang Y; Dai B; Allton KL; Hughes TG; Siangco C; Augustine JJ; Kang Y; McDaniel JM; Xiong S; Koay EJ; McAllister F; Bristow CA; Heffernan TP; Maitra A; Liu B; Barton MC; Wasylishen AR; Fleming JB; Lozano G
Cancer Discov; 2021 Aug; 11(8):2094-2111. PubMed ID: 33839689
[TBL] [Abstract][Full Text] [Related]
35. PARPis and Other Novel, Targeted Therapeutics in Pancreatic Adenocarcinoma.
Chapin WJ; Reiss KA
Hematol Oncol Clin North Am; 2022 Oct; 36(5):1019-1032. PubMed ID: 36154785
[TBL] [Abstract][Full Text] [Related]
36. Anticipating resistance to KRAS inhibition: a novel role for USP21 in macropinocytosis regulation.
Crawford HC
Genes Dev; 2021 Oct; 35(19-20):1325-1326. PubMed ID: 34599002
[TBL] [Abstract][Full Text] [Related]
37. Oncogenic KRAS engages an RSK1/NF1 pathway to inhibit wild-type RAS signaling in pancreatic cancer.
Cheng DK; Oni TE; Thalappillil JS; Park Y; Ting HC; Alagesan B; Prasad NV; Addison K; Rivera KD; Pappin DJ; Van Aelst L; Tuveson DA
Proc Natl Acad Sci U S A; 2021 May; 118(21):. PubMed ID: 34021083
[TBL] [Abstract][Full Text] [Related]
38. Precision medicine for KRAS wild-type pancreatic adenocarcinomas.
Ben-Ammar I; Rousseau A; Nicolle R; Tarabay A; Boige V; Valery M; Pudlarz T; Malka D; Gelli M; Fernandez-De-Sevilla E; Fuerea A; Tanguy ML; Rouleau E; Barbe R; Mathieu JRR; Jaulin F; Smolenschi C; Hollebecque A; Ducreux M; Boileve A
Eur J Cancer; 2024 Jan; 197():113497. PubMed ID: 38134480
[TBL] [Abstract][Full Text] [Related]
39. KRAS wild-type pancreatic ductal adenocarcinoma: molecular pathology and therapeutic opportunities.
Luchini C; Paolino G; Mattiolo P; Piredda ML; Cavaliere A; Gaule M; Melisi D; Salvia R; Malleo G; Shin JI; Cargnin S; Terrazzino S; Lawlor RT; Milella M; Scarpa A
J Exp Clin Cancer Res; 2020 Oct; 39(1):227. PubMed ID: 33115526
[TBL] [Abstract][Full Text] [Related]
40. Combination Therapies with CDK4/6 Inhibitors to Treat KRAS-Mutant Pancreatic Cancer.
Goodwin CM; Waters AM; Klomp JE; Javaid S; Bryant KL; Stalnecker CA; Drizyte-Miller K; Papke B; Yang R; Amparo AM; Ozkan-Dagliyan I; Baldelli E; Calvert V; Pierobon M; Sorrentino JA; Beelen AP; Bublitz N; Lüthen M; Wood KC; Petricoin EF; Sers C; McRee AJ; Cox AD; Der CJ
Cancer Res; 2023 Jan; 83(1):141-157. PubMed ID: 36346366
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
